Incyte Corp INCY
We take great care to ensure that the data presented and summarized in this overview for INCYTE CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INCY
View all-
Baker Bros. Advisors LP New York, NY30.7MShares$2.15 Billion22.18% of portfolio
-
Black Rock Inc. New York, NY21.4MShares$1.49 Billion0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA20MShares$1.4 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA14.9MShares$1.04 Billion0.55% of portfolio
-
State Street Corp Boston, MA10MShares$702 Million0.03% of portfolio
-
Aqr Capital Management LLC Greenwich, CT6.74MShares$471 Million0.43% of portfolio
-
Geode Capital Management, LLC Boston, MA4.21MShares$294 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.71MShares$260 Million0.36% of portfolio
-
Lsv Asset Management Chicago, IL3.64MShares$255 Million0.53% of portfolio
-
Invesco Ltd. Atlanta, GA3.17MShares$222 Million0.04% of portfolio
Latest Institutional Activity in INCY
Top Purchases
Top Sells
About INCY
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Insider Transactions at INCY
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 03
2025
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
10,903
-21.53%
|
$741,404
$68.15 P/Share
|
Jul 03
2025
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Open market or private sale
|
Direct |
8,617
-9.7%
|
$585,956
$68.16 P/Share
|
Jul 02
2025
|
Paula J Swain EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
6,285
-5.86%
|
$427,380
$68.17 P/Share
|
Jul 02
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
599
-2.21%
|
$40,732
$68.61 P/Share
|
Jul 02
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
599
+2.16%
|
$34,742
$58.06 P/Share
|
Jul 02
2025
|
Barry P Flannelly EVP & General Manager US |
SELL
Payment of exercise price or tax liability
|
Direct |
9,055
-15.17%
|
$615,740
$68.17 P/Share
|
Jul 02
2025
|
Christiana Stamoulis EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,589
-8.98%
|
$788,052
$68.17 P/Share
|
Jul 02
2025
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,714
-10.16%
|
$864,552
$68.17 P/Share
|
Jul 02
2025
|
Thomas Tray Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
897
-4.08%
|
$60,996
$68.17 P/Share
|
Jul 02
2025
|
Herve Hoppenot Special Advisor to the CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
42,769
-7.51%
|
$2,908,292
$68.17 P/Share
|
Jul 02
2025
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Payment of exercise price or tax liability
|
Direct |
6,809
-12.82%
|
$463,012
$68.17 P/Share
|
Jul 02
2025
|
William Meury Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+50.0%
|
-
|
Jun 30
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
984
+0.01%
|
-
|
Jun 30
2025
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
361
+1.55%
|
$24,548
$68.1 P/Share
|
Jun 30
2025
|
Mohamed Khairie Issa EVP, Head of US Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
27,812
+26.67%
|
-
|
Jun 30
2025
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+1.77%
|
$24,956
$68.1 P/Share
|
Jun 26
2025
|
Herve Hoppenot Special Advisor to the CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,016
+1.05%
|
-
|
Jun 10
2025
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+10.78%
|
-
|
Jun 10
2025
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+11.53%
|
-
|
Jun 10
2025
|
Otis W Brawley Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+18.29%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 554K shares |
---|---|
Exercise of conversion of derivative security | 16.2K shares |
Payment of exercise price or tax liability | 126K shares |
---|---|
Open market or private sale | 119K shares |